<DOC>
	<DOCNO>NCT00002868</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining interferon alfa high-dose chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness interferon alfa without peripheral stem cell transplantation treat patient newly diagnose chronic myelogenous leukemia chronic phase .</brief_summary>
	<brief_title>Interferon-alfa With Without Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival patient chronic myelogenous leukemia chronic phase treat interferon alfa without cytarabine v autologous peripheral blood stem cell transplantation follow interferon alfa without cytarabine . II . Compare time blast transformation treatment regimens patient . III . Compare number patient revert Philadelphia chromosome ( Ph ) negative hematopoiesis treatment regimen . IV . Compare complete major cytogenetic response rate patient one year receive treatment regimen annually thereafter . V. Compare hematological remission rate patient receive treatment regimen . VI . Compare duration hematological remission impact survival blastic transformation patient receive treatment regimen . VII . Compare duration Ph negative hemapoiesis impact survival blastic transformation patient receive treatment regimen . VIII . Determine number patient fail one treatment regimen rescue alternative . IX . Compare quality life patient treatment regimen . X . Determine number patient tolerate two regimen . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . Arm I : Patients undergo mobilization chemotherapy regimen center 's choice , either follow : Patients receive idarubicin IV 10 minute , etoposide IV 2 hour , cytarabine IV 2 hour day 1-3 ; filgrastim ( G-CSF ) subcutaneously ( SC ) start day 11 continue blood count recover . OR Patients receive hydroxyurea IV daily neutrophil count drop 1,000/mm3 platelet count drop 20,000/mm3 follow G-CSF SC 3 consecutive day leukapheresis complete . Following mobilization therapy , patient undergo leukapheresis within 6 month diagnosis . Patients undergo cytoreductive therapy consist oral busulfan day -5 -2 . Autologous peripheral blood stem cell infuse day 0 . Once blood count recover , patient receive interferon alfa SC 3 time week 8 week , daily least total 6 month disease progression . At discretion treat physician , patient may also receive cytarabine SC day 10 day month , begin 2 week interferon alfa therapy begin continue complete cytogenetic response achieve . Arm II : Patients receive interferon alfa SC 3 time week 4 week , daily 6 month . If hematological remission achieve 6 month , interferon treatment continue least another 6 month disease progression . At discretion treat physician , patient may also receive cytarabine arm I . Quality life assess defined interval . Patients follow least 2 year . PROJECTED ACCRUAL : Approximately 744 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose chronic myelogenous leukemia chronic phase Philadelphia chromosome and/or BCR/ABL positive Initial diagnosis within 6 month randomization No clinical laboratory evidence acceleration blastic disease No contraindication peripheral blood cell stem cell collection prior treatment PATIENT CHARACTERISTICS : Age : 15 65 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No major organ impairment Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interferon alfa Chemotherapy : Prior hydroxyurea allow Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
</DOC>